Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of sequential satraplatin and erlotinib versus erlotinib alone in elderly patients with advanced non-small cell lung cancer
2006-001973-10Phase 2Completed
- Sponsor
- GPC Biotech AG
- Start
- Nov 2006
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Sequential satraplatin and erlotinib with Single-agent erlotinib (2 arms). Primary endpoint: Progression-free survival. Started Nov 2006; status: completed.
02
Drugs
satraplatinerlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-001973-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001973-10.